Compounds > 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid
Page last updated: 2024-10-21

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Idiopathic Parkinson Disease

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid has been researched along with Idiopathic Parkinson Disease in 2 studies

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pollack, AE1
Haisley, EC1
Klockgether, T1
Turski, L1

Other Studies

2 other studies available for 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Idiopathic Parkinson Disease

ArticleYear
NMDA glutamate receptor stimulation is required for the expression of D2 dopamine mediated responses in apomorphine primed 6-hydroxydopamine lesioned rats.
    Brain research, 2001, Apr-06, Volume: 897, Issue:1-2

    Topics: Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Denervation; Dizocilpine Maleate; Dopamine

2001
NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats.
    Annals of neurology, 1990, Volume: 28, Issue:4

    Topics: Animals; Dizocilpine Maleate; Drug Synergism; Electromyography; Levodopa; Male; Methyltyrosines; Mot

1990